KNE Kane Biotech Inc

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® in the journal Pathogens.

Pathogens is an international, peer-reviewed, open access journal focusing on pathogens and pathogen-host interactions. The article, entitled “Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme,” is first authored by Dr. Jeffrey B. Kaplan, the discoverer of the DispersinB® enzyme and a consultant to Kane Biotech. Dr. Kaplan is currently a scientist in the Laboratory for Skin Research at the Galilee Medical Center in Nahariya, Israel. Dr. Kaplan was previously a Professor at American University in Washington DC, an Associate Professor at Rutgers School of Dental Medicine in Newark NJ, and a Senior Scientist at Pfizer Inc. He is the recipient of numerous awards including a Fulbright Scholar Award.

“DispersinB® has been studied in more than 70 research laboratories in 21 different countries, including such prestigious institutions as Harvard Medical School and the Mayo Clinic,” said Dr. Jeffrey Kaplan. “DispersinB® exhibits antibiofilm activity against more than 25 species of bacteria, suggesting that the enzyme may have applicability as a broad-spectrum antibiofilm agent. Considering Kane Biotech’s extensive biocompatibility testing and formulation studies involving DispersinB®, I am optimistic about the commercial potential of products the Company has in development that contain this enzyme.”

The article can be viewed here.

In addition to this publication, Kane Biotech is presenting the following ongoing research:

• The antibiofilm properties of revyve™ Antimicrobial Wound Gel Spray to treat complex combat wounds at the Military Health System Research Symposium (MHSRS) (August 26-29, 2024).
• The antibiofilm properties and compatibility with different dressings of revyve™ Antimicrobial Wound Gel at the Symposium on Advance Wound Care (SAWC) (October 2-5, 2024).

Earlier this year, Kane presented research on its novel thermo-reversible antimicrobial hydrogel spray with effective antibiofilm properties to treat complex combat wounds at the Special Operations Medical Association (SOMA) 2024 Scientific Assembly.

“These ongoing presentations in peer-reviewed meetings demonstrate Kane’s ongoing commitment to helping clinicians understand biofilms,” said Dr. Robert Huizinga, Board Chair. “It also presents the potential treatments available to them to treat the underlying cause of chronic wound infections. We look forward to further advancing the science of biofilms at future industry gatherings.”   

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (68 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:

Marc Edwards			Ray Dupuis
Chief Executive Officer			Chief Financial Officer
Kane Biotech Inc			Kane Biotech Inc
medwards@kanebiotech.com			rdupuis@kanebiotech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking InformationThis press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.